AstraZeneca and Silence Therapeutics entered a March alliance worth up to $4.08bn for the discovery and development of siRNA drugs for cardiovascular, renal, metabolic and respiratory diseases, while the top April deal was a $3.9bn tie up between Fate Therapeutics and Janssen for iPSC-derived cell-based cancer immunotherapies.

A review of biopharma start-up dealmaking and financing activity from January through March 2020, based on data from Biomedtracker.

Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn between them.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.

Recent venture capital rounds funded the start-ups Airway, Alladapt, ALX Oncology, Azafaros, CANbridge, NeoTx, Spruce and Transcenta.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.